These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 8874986)
21. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS; Fong NT Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596 [TBL] [Abstract][Full Text] [Related]
22. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. Arntz HR Atherosclerosis; 1999 Sep; 147 Suppl 1():S17-21. PubMed ID: 10575058 [TBL] [Abstract][Full Text] [Related]
23. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Crouse JR; Byington RP; Bond MG; Espeland MA; Sprinkle JW; McGovern M; Furberg CD Control Clin Trials; 1992 Dec; 13(6):495-506. PubMed ID: 1334821 [TBL] [Abstract][Full Text] [Related]
24. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins. Richter WO; Jacob BG; Schwandt P Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291 [TBL] [Abstract][Full Text] [Related]
25. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685 [TBL] [Abstract][Full Text] [Related]
26. A clinical focus on statins. Auer J; Eber B Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709 [TBL] [Abstract][Full Text] [Related]
27. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson RS Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000 [TBL] [Abstract][Full Text] [Related]
28. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Gotto AM Am J Cardiol; 2005 Sep; 96(5A):34F-38F. PubMed ID: 16126021 [TBL] [Abstract][Full Text] [Related]
29. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Furberg CD; Adams HP; Applegate WB; Byington RP; Espeland MA; Hartwell T; Hunninghake DB; Lefkowitz DS; Probstfield J; Riley WA Circulation; 1994 Oct; 90(4):1679-87. PubMed ID: 7734010 [TBL] [Abstract][Full Text] [Related]
30. Statins in the 21st century: end of the simple story? Doggrell SA Expert Opin Investig Drugs; 2001 Sep; 10(9):1755-66. PubMed ID: 11772284 [TBL] [Abstract][Full Text] [Related]
31. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Yokoyama M; Origasa H; Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313 [TBL] [Abstract][Full Text] [Related]
32. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023 [TBL] [Abstract][Full Text] [Related]
33. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Haria M; McTavish D Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747 [TBL] [Abstract][Full Text] [Related]
34. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline. Kawaguchi A; Mitsudo K; Nobuyoshi M; Minamino R; Hayasaki K; Nakashima M; Yamamoto A; J Cardiovasc Risk; 2002 Feb; 9(1):7-16. PubMed ID: 11984212 [TBL] [Abstract][Full Text] [Related]
35. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335 [TBL] [Abstract][Full Text] [Related]
36. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Nissen SE Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025 [TBL] [Abstract][Full Text] [Related]